5 Years of Biosimilars in the US: What Have We Learned?
PharmaPhorum, Sean McGowan
Biologics have created revolutionary treatment options that have transformed the care journey for hundreds of millions of patients worldwide. In some cases, a painless injection is all that is now needed to mitigate and manage various cancers, rheumatoid arthritis, Crohn’s Disease, and other life-altering illnesses.
With patents on originator biologic medicines beginning to expire in the United States, there’s a growing opportunity for biosimilars to enter the market as alternative therapeutic options at lower prices. In fact, the success of biosimilars in Europe has given the United States a glimpse into how these therapies can increase patient access to the benefits of the most innovative therapies.
For the full article, check out PharmaPhorum.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.